IGF2BP3 and cancer: Guevara-Aguirre et al. (2011) demonstrated that low IGF2BP3 expression could protect bone cells from cancer. Indeed, high protein levels of IGF2BP3 correlate with malignant transformation of bone cells, promoting proliferation, drug resistance and metastasis. Moreover, in vitro experiments on ES cell lines (Mancarella et al., 2018) have shown that silencing IGF2BP3 drastically reduces cell migration and growth.